ICAD iCAD, Inc.: Market Capitalization to Book Value Ratio

icadmed.com (ICAD) - corporate logo

iCAD, Inc. (ICAD) is reducing its reliance on hardware by developing high-margin cloud SaaS solutions. The expansion of ProFound AI B2B subscriptions into radiology centers aims to capture the early cancer detection market. Changes in the revaluation of balance sheet capital demonstrate asset value dynamics, where the value of 3.42 records the metric level. Leadership in AI mammography diagnostics ensures a steady stream of licensing payments.

iCAD (ICAD) - Market Capitalization to Book Value Ratio from 07/04/2022 to 08/02/2025
Finished products of iCAD, Inc.

The asset's fundamental risks are determined by the gap between the market price and the real value of capital. For iCAD, Inc., which develops AI cancer diagnostics, it is critical to understand how the market values intellectual assets relative to the balance sheet. This chart of the market capitalization to book value ratio reflects this balance, where the current value of 3.42 serves as a marker for whether the business is overvalued or undervalued. A low ratio indicates a margin of safety, although it requires a review of the debt load. A high figure confirms investor confidence in the scalability of robotic systems.

Main competitors

Market Capitalization to Book Value Ratio BeiGene Ltd|halozyme.com (HALO) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio RVMD|Market Cap to Net Assets Ratio Ascentage Pharma Group International|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio URGN (UroGen Pharma Corp)|BCAX - Market Value to Book Value Ratio|Capitalization to Book Value Ratio personalis.com PSNL|ERAS: Market Capitalization to Book Value Ratio|DCTH - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio YMAB|AURA (Aura Corp) - Market-to-Book Ratio|CADL - Market Value to Book Value Ratio|Market Value to Book Value accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Market Cap to Net Assets Ratio|Market Value to Book Value Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Market Capitalization to Book Value Ratio|HURA - Market Cap to Net Assets Ratio|Protara Therapeutics - Market Cap to Net Assets Ratio|FATE: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Market Value to Book Value|Market Capitalization to Book Value Ratio CSBR (Champions Oncology Inc)|Market-to-Book Ratio XBiotech USA|CVM (CEL-SCI Corporation) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ostherapies.com (OSTX)|Radiopharm Theranostics - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Artiva Biotherapeutics Inc. ARTV|Adlai Nortye Limited - Market Capitalization to Book Value Ratio|VERU - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Tempest Therapeutics|Capitalization to Book Value Ratio Xilio Therapeutics|RENB - Market Cap to Net Assets Ratio|Market Value to Book Value Mural Bio|KAPA (Kairos Pharma Ltd) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value OKUR (onkuretherapeutics.com)|GDTC - Market Value to Book Value Ratio|Capitalization to Book Value Ratio Curis Inc. CRIS|APLM: Market Capitalization to Book Value Ratio|Tharimmune Inc (THAR) - Market Cap to Net Assets Ratio|advanbiomed.com - Market Cap to Net Assets Ratio|Genprex Inc (GNPX) - Market Capitalization to Book Value|CLDI: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value sunshinebiopharma.com|Market Capitalization to Book Value Ratio XBIO (Xenetic Biosciences)|Market Cap to Net Assets Ratio Salarius Pharmaceuticals Inc (SLRX)|Market Capitalization to Book Value Ratio PPBT (Purple Biotech Corp)|Market Capitalization to Book Value Ratio American Oncology Network Inc AONC|BeiGene, Ltd. (BGNE) - Market Capitalization to Book Value Ratio|CKPT - Capitalization to Book Value Ratio|ELEV (Elevation Oncology) - Market Capitalization to Book Value Ratio|Ikena Oncology (IKNA) - Market Cap to Net Assets Ratio|NTBL (Notable Labs Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio VIRX|Market Value to Book Value Ratio MorphoSys AG MOR|Capitalization to Book Value Ratio nayabiosciences.com (NAYA)|Ascentage Pharma - Market Capitalization to Book Value Ratio